Cite
HARVARD Citation
Bézard, M. et al. (2021). Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis. European journal of heart failure. pp. 264-274. [Online].